MIGDAL HA'EMEQ, Israel, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (NASDAQ:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid-based nutritional ingredients and medical foods, today announced that the Company will host a VAYA Pharma Analyst and Investor Day at Four Times Square in New York City on November 19, 2015, beginning at 12pm ET.
The meeting will feature presentations from VAYA Pharma's Chief Executive Officer, Rob Crim, and its executive team on VAYA Pharma's growth strategies, research and development and marketing programs.
Enzymotec will host a live webcast of the event at www.enzymotec.com. The webcast and related presentation materials will also be archived on the website.
Prior registration is required with The Ruth Group.
About VAYA Pharma
VAYA Pharma is a specialty pharmaceutical division of Enzymotec Ltd. dedicated to the discovery, development, manufacture and marketing of innovative lipid-based compositions familiar to the human body for addressing disorders that are impacted by lipid imbalances.
VAYA Pharma's medical food portfolio addresses three therapeutic segments: ADHD (Vayarin(R)), Early Memory Impairment (Vayacog(R)) and Hypertriglyceridemia (Vayarol(R)). VAYA Pharma products are available in the U.S. only by prescription under the supervision of a physician. VAYA Pharma USA is headquartered in Baltimore, Maryland. For more information, visit www.vayapharma.com
About Enzymotec Ltd.
Enzymotec Ltd. is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-active lipid ingredients, as well as final products, based on sophisticated processes and technologies. For more information, visit www.enzymotec.com.